These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19153776)

  • 21. Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.
    de Groot T; Doornebal J; Christensen BM; Cockx S; Sinke AP; Baumgarten R; Bedford JJ; Walker RJ; Wetzels JFM; Deen PMT
    Am J Physiol Renal Physiol; 2017 Sep; 313(3):F669-F676. PubMed ID: 28615247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
    Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
    Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD.
    Lai CC; Wang YH; Wang CY; Wang HC; Yu CJ; Chen L
    Int J Chron Obstruct Pulmon Dis; 2018; 13():867-874. PubMed ID: 29563786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gradient washout and secondary nephrogenic diabetes insipidus after brain injury in an infant: a case report.
    Chang N; Mariano K; Ganesan L; Cooper H; Kuo K
    J Med Case Rep; 2020 Oct; 14(1):183. PubMed ID: 33036650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
    Bakris GL; Weir MR
    Arch Intern Med; 2000 Mar; 160(5):685-93. PubMed ID: 10724055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
    Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.
    Shen J; Huang YM; Song XN; Hong XZ; Wang M; Ling W; Zhang XX; Zhao HL
    J Renin Angiotensin Aldosterone Syst; 2016 Jul; 17(3):. PubMed ID: 27377659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
    Powers B; Greene L; Balfe LM
    J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Study of Morphological Changes in Renal Afferent Arterioles Induced by Angiotensin II Type 1 Receptor Blockers in Hypertensive Patients.
    Nagai Y; Yamabe F; Sasaki Y; Ishii T; Nakanishi K; Nakajima K; Shibuya K; Mikami T; Akasaka Y; Urita Y; Yamanaka N
    Kidney Blood Press Res; 2020; 45(2):194-208. PubMed ID: 31945766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M; Carrero JJ; Szummer K; Åkerblom A; Edfors R; Spaak J; Jacobson SH; Andell P; Lindhagen L; Jernberg T
    J Am Coll Cardiol; 2016 Apr; 67(14):1687-97. PubMed ID: 27056774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.
    Onuigbo MA
    Nephron Clin Pract; 2009; 113(2):c63-9, discussion c70. PubMed ID: 19602900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine osmolality, cyclic AMP and aquaporin-2 in urine of patients under lithium treatment in response to water loading followed by vasopressin administration.
    Wilting I; Baumgarten R; Movig KL; van Laarhoven J; Apperloo AJ; Nolen WA; Heerdink ER; Knoers NV; Egberts AC
    Eur J Pharmacol; 2007 Jul; 566(1-3):50-7. PubMed ID: 17466972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T; Pohl M; Misselwitz J; John U
    Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.